These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 29209911)
1. MALDI Mass Spectrometry Imaging for Evaluation of Therapeutics in Colorectal Tumor Organoids. Liu X; Flinders C; Mumenthaler SM; Hummon AB J Am Soc Mass Spectrom; 2018 Mar; 29(3):516-526. PubMed ID: 29209911 [TBL] [Abstract][Full Text] [Related]
2. Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. Buck A; Halbritter S; Späth C; Feuchtinger A; Aichler M; Zitzelsberger H; Janssen KP; Walch A Anal Bioanal Chem; 2015 Mar; 407(8):2107-16. PubMed ID: 25311193 [TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. Deyme L; Barbolosi D; Mbatchi LC; Tubiana-Mathieu N; Ychou M; Evrard A; Gattacceca F Cancer Chemother Pharmacol; 2021 Aug; 88(2):247-258. PubMed ID: 33912999 [TBL] [Abstract][Full Text] [Related]
4. Quantification of Irinotecan in Single Spheroids Using Internal Standards by MALDI Mass Spectrometry Imaging. Wang Y; Hummon AB Anal Chem; 2023 Jun; 95(24):9227-9236. PubMed ID: 37285205 [TBL] [Abstract][Full Text] [Related]
5. Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements. Calandra E; Posocco B; Crotti S; Marangon E; Giodini L; Nitti D; Toffoli G; Traldi P; Agostini M Anal Bioanal Chem; 2016 Jul; 408(19):5369-77. PubMed ID: 27235158 [TBL] [Abstract][Full Text] [Related]
6. Anticancer Drug Affects Metabolomic Profiles in Multicellular Spheroids: Studies Using Mass Spectrometry Imaging Combined with Machine Learning. Tian X; Zhang G; Zou Z; Yang Z Anal Chem; 2019 May; 91(9):5802-5809. PubMed ID: 30951294 [TBL] [Abstract][Full Text] [Related]
7. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. Mallick P; Shah P; Gandhi A; Ghose R Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of therapeutics in three-dimensional cell culture systems by MALDI imaging mass spectrometry. Liu X; Weaver EM; Hummon AB Anal Chem; 2013 Jul; 85(13):6295-302. PubMed ID: 23724927 [TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion of irinotecan and EmboCept Kauffels A; Kitzmüller M; Gruber A; Nowack H; Bohnenberger H; Spitzner M; Kuthning A; Sprenger T; Czejka M; Ghadimi M; Sperling J Clin Exp Metastasis; 2019 Feb; 36(1):57-66. PubMed ID: 30680598 [TBL] [Abstract][Full Text] [Related]
10. Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A J Pharmacol Sci; 2019 May; 140(1):20-25. PubMed ID: 31105026 [TBL] [Abstract][Full Text] [Related]
11. MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures. Liu X; Lukowski JK; Flinders C; Kim S; Georgiadis RA; Mumenthaler SM; Hummon AB Anal Chem; 2018 Dec; 90(24):14156-14164. PubMed ID: 30479121 [TBL] [Abstract][Full Text] [Related]
12. MALDI-TOF MS imaging of metabolites with a N-(1-naphthyl) ethylenediamine dihydrochloride matrix and its application to colorectal cancer liver metastasis. Wang J; Qiu S; Chen S; Xiong C; Liu H; Wang J; Zhang N; Hou J; He Q; Nie Z Anal Chem; 2015 Jan; 87(1):422-30. PubMed ID: 25474421 [TBL] [Abstract][Full Text] [Related]
13. Spatially resolved metabolic distribution for unraveling the physiological change and responses in tomato fruit using matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI). Nakamura J; Morikawa-Ichinose T; Fujimura Y; Hayakawa E; Takahashi K; Ishii T; Miura D; Wariishi H Anal Bioanal Chem; 2017 Feb; 409(6):1697-1706. PubMed ID: 27933363 [TBL] [Abstract][Full Text] [Related]
14. Drug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry. LaBonia GJ; Lockwood SY; Heller AA; Spence DM; Hummon AB Proteomics; 2016 Jun; 16(11-12):1814-21. PubMed ID: 27198560 [TBL] [Abstract][Full Text] [Related]
15. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. de Man FM; Goey AKL; van Schaik RHN; Mathijssen RHJ; Bins S Clin Pharmacokinet; 2018 Oct; 57(10):1229-1254. PubMed ID: 29520731 [TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A Eur J Clin Pharmacol; 2019 Apr; 75(4):529-542. PubMed ID: 30610273 [TBL] [Abstract][Full Text] [Related]
17. MALDI imaging mass spectrometry and chemometric tools to discriminate highly similar colorectal cancer tissues. Mas S; Torro A; Fernández L; Bec N; Gongora C; Larroque C; Martineau P; de Juan A; Marco S Talanta; 2020 Feb; 208():120455. PubMed ID: 31816732 [TBL] [Abstract][Full Text] [Related]
18. Sample preparation strategies for high-throughput mass spectrometry imaging of primary tumor organoids. Johnson J; Sharick JT; Skala MC; Li L J Mass Spectrom; 2020 Apr; 55(4):e4452. PubMed ID: 31661714 [TBL] [Abstract][Full Text] [Related]
19. Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation. Parvez MM; Basit A; Jariwala PB; Gáborik Z; Kis E; Heyward S; Redinbo MR; Prasad B Drug Metab Dispos; 2021 Aug; 49(8):683-693. PubMed ID: 34074730 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. Liu Z; Martin JH; Liauw W; McLachlan SA; Link E; Matera A; Thompson M; Jefford M; Hicks RJ; Cullinane C; Hatzimihalis A; Campbell I; Crowley S; Beale PJ; Karapetis CS; Price T; Burge ME; Michael M Eur J Clin Pharmacol; 2022 Jan; 78(1):53-64. PubMed ID: 34480602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]